Treatment Approaches to Major Depressive Disorder Relapse
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objective: Although continuing antidepressant treatment after patients have responded to medication has been shown to greatly reduce the risk of relapse, this risk is not eliminated. A number of theories have been proposed to account for this apparent loss of efficacy. A common initial approach to managing relapse is to increase the dose of antidepressant. We prospectively evaluated the likelihood of response to increasing the fluoxetine doses in patients relapsing during a long-term efficacy study of two fluoxetine dosing regimens. Method: Patients meeting the DSM-IV criteria for major depressive disorder with modified HAMD17 scores ≧18 and CGI-severity scores ≧4 were treated for 13 weeks with open-label 20 mg/day fluoxetine in a multicenter US study. Responders (n = 501) were randomized to 20 mg fluoxetine daily, placebo, or 90 mg enteric-coated fluoxetine weekly for 25 weeks of double-blind continuation treatment. If the patients relapsed during the continuation phase, they were offered a 25-week optional rescue treatment phase during which the study medication dose was increased as follows: (1) patients on placebo had treatment with fluoxetine 20 mg/day reinitiated, (2) patients on fluoxetine 20 mg/day had their dose increased to 40 mg/day, and (3) patients on a 90-mg weekly dose had their dose increased to 90 mg twice a week. The results of the rescue phase for the latter two groups who relapsed while on continuation treatment with fluoxetine are reported. Response was defined as a 50% reduction in the modified HAMD17 score since time of relapse and a CGI-severity score ≤2. Additional efficacy analyses included HAMD and CGI-severity changes from baseline to endpoint. Safety measures included assessment of treatment-emergent adverse events, vital signs, and laboratory measures. Results: Overall, patients relapsing during the continuation treatment responded to an increased dose (57% of the 40-mg-daily group and 72% of the enteric-coated 90-mg-twice-weekly group). Mean modified HAMD17 scores decreased from a mean of approximately 20 to below 8 and were maintained for up to 6 months in the responders. Thirty-five percent of patients either did not respond or initially responded but again relapsed after augmentation of medication. Conclusions: The patients relapsing after initially responding to fluoxetine can benefit from an increase in fluoxetine dose. These results also generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant. Increasing enteric-coated fluoxetine 90 mg once weekly to twice weekly appeared to be as well-tolerated and effective in restoring response as increasing a daily fluoxetine dose from 20 to 40 mg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One patient out of five who initially responded to dose increase relapsed again during the 25-week trial.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [16]
In the citing paper
“In a randomized controlled study,16 fluoxetine was administered at 20 mg daily or 90 mg weekly dose. About one-third of patients relapsed within an average of 107 days of maintenance treatment.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [16]
In the citing paper
“The effectiveness of increasing the medication if relapse took place was assessed: 57% of patients receiving the daily dosage and 72% those with the weekly dosage displayed a response to the dose increase.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [16]
In the citing paper
“Illness behavior, in its experiential, cognitive and behavioral aspects, is an additional important source of counter-therapeutic attitudes [62].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [62]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
Simon, G. E. (1996) · JAMA · doi:10.1001/jama.275.24.1897 · Cited by 294
Reimherr, F. W., Amsterdam, J. D., Quitkin, F. M., Rosenbaum, J. F., Fava, M., Zajecka, J., Beasley, Jr., Michelson, D., Roback, P., & Sundell, K. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1247 · Cited by 204
Lithium-discontinuation-induced refractoriness: preliminary observations
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.12.1727 · Cited by 163
Loss of Antidepressant Efficacy During Maintenance Therapy: Possible Mechanisms and Treatments
Byrne, S. E., & Rothschild, A. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0602 · Cited by 149
Fredman, S. J., Fava, M., Kienke, A. S., White, C. N., Nierenberg, A. A., & Rosenbaum, J. F. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0602 · Cited by 132
Thase, M. E., Frank, E., Mallinger, A. G., Hamer, T., & Kupfer, D. J. (1992) · PubMed · Cited by 114
New approaches to the treatment of refractory depression.
Fava, M. (2000) · PubMed · Cited by 114
Self-citationStewart, J. W., Quitkin, F. M., McGrath, P. J., Amsterdam, J., Fava, M., Fawcett, J., Reimherr, F., Rosenbaum, J., Beasley, C., & Roback, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.334 · Cited by 113 · cited 1×
“conducted the first and only pilot, prospective study in the literature on 12 patients who had relapsed after being switched to placebo as part of a double-blind maintenance treatment study with desipramine. These 12 patients received open treatment with desipramine at a dose equal or greater than the continuation pha…”
BackgroundInfluentialManagement of nonresponse and intolerance: switching strategies.
D, M. F. M. (2000) · PubMed · Cited by 103
Self-citationDunn, R. L., Donoghue, J. M., Ozminkowski, R. J., Stephenson, D., & Hylan, T. R. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300204 · Cited by 100
Effect of antidepressant therapy on health care utilization and costs in primary care
(1997) · Psychiatric Services · doi:10.1176/ps.48.11.1420 · Cited by 73
Schmidt, M. E., Fava, M., Robinson, J. M., & Judge, R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1107 · Cited by 68
Self-citationRelapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
D, M. F. M., Rappe, S., Pava, J. A., Nierenberg, A. A., Alpert, J. E., & Rosenbaum, J. F. (1995) · PubMed · Cited by 63
Pharmacotherapy of depressive disorders
Centres, W. M. H. C. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90043-8 · Cited by 60
Tolerance to therapeutic effects of antidepressants
Cohen, B. M., & Baldessarini, R. J. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.489 · Cited by 59
Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study
Jarrett, R. B., Kraft, D., Schaffer, M., Witt-Browder, A., Risser, R., Atkins, D. H., & Doyle, J. (2000) · Psychotherapy and Psychosomatics · doi:10.1159/000012401 · Cited by 48
MANN, J. J. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198312000-00007 · Cited by 35
Holding On: Depression, Sensitization by Antidepressant Drugs, and the Prodigal Experts
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288992 · Cited by 33 · cited 1×
“Alternatively, one could hypothesize that a sensitization phenomenon may have occurred, with the development of tolerance to the effect of the antidepressant [”
BackgroundManagement of Major Depression in the Primary Care Setting
Mischoulon, D., McColl-Vuolo, R., Howarth, S., Lagomasino, I. T., Alpert, J. E., Nierenberg, A. A., & Fava, M. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056233 · Cited by 25
Streja, D. A., Hui, R. L., Streja, E., & McCombs, J. S. (1999) · PubMed · Cited by 23
Strategies and tactics in the management of maintenance treatment for depressed patients.
Rush, A. J. (1999) · PubMed · Cited by 22
Retreatment for relapse following desipramine discontinuation in dysthymia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.926 · Cited by 15
Differential Responses to a Single Antidepressant in Recurrent Episodes of Major Depression
Remillard, A. J., Blackshaw, S. L., & Dangor, A. (1994) · Psychiatric Services · doi:10.1176/ps.45.4.359 · Cited by 12
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Laje, G., Fava, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 474
Fava, G. A., & Ruini, C. (2003) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(03)00019-3 · Cited by 386
Metadata
- Authors
- Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 71
- Issue
- 4
- Pages
- 190-194
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2083910351
- Cited by
- 60
- References
- 26
- Citations by year
- 2025: 1 · 2024: 3 · 2022: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2015: 1 · 2014: 2 · 2013: 1
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- relapse, fluoxetine, continuation treatment, salvage therapy, antidepressant efficacy, long-term maintenance, treatment-emergent adverse events, treatment-resistant depression, treatment-emergent mania
- MeSH terms
- Adult, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Prospective Studies, Recurrence, Severity of Illness Index, Tablets, Enteric-Coated, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.